

## **REMARKS**

### **I. Response to Restriction Requirement**

In response to the restriction requirement mailed on August 13, 2003, applicant elect Group III, claims 1, 7-10 and 18-20, with traverse. The basis of the traversal is that numerous dependent claims are not properly restricted as they merely add elements to the elected invention of Class I + Class II antigens or other alloantigens. For example, claims 11-13 add viral antigens, claims 14 and 15 add cytokines, and claims 16 and 17 add costimulatory molecules.<sup>1</sup> If claim 1 is found allowable without reliance on the content of these claims, then the additional limitations set forth in claims 11-17 will not even come into play. Therefore, applicants respectfully submit that withdrawal of these claims is premature in light of the perceived allowability of claim 1.

### **II. Support for Amendments**

Amendments to the claims and new claims are supported generally throughout the application, but in particular, support may be derived as follows: claim 1 – page 26, lines 16-17; claim 14 – page 31, line 10; claim 32 – page 26, lines 20-21; claim 33 – page 32, lines 20-21; claim 34 – page 29, lines 14-20; claim 35 – page 31, lines 8-9; claim 36 – page 31, lines 12-15. Thus, no new matter is presented by the amended/new claims.


---

<sup>1</sup> New claims 35 and 35 add immunostimulatory compounds, and are therefore presumed to be outside the scope of the initial restriction as well.

### **III. Conclusion**

Applicants respectfully request entry of the amendments and examination of the claims as set forth in §I, above. Should the examiner have any questions regarding this submission, a telephone call to the undersigned is invited.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: January 22, 2004